Health Catalyst Inc Expected to Report Break-even EPS in Q1 2025

Summary

Health Catalyst Inc expects to report breakeven earnings per share for Q1 2025, with revenue growing by 5.9% to $79.169 million. Analysts estimate the target median price at $7.25, higher than the last closing price of $4.07. Analysts generally rate the stock as ‘Buy’ with no sell recommendations. Company’s guidance includes $4 million EBITDA. Recent earnings expectations decreased slightly by 1.1% over the past three months. Reuters

Impact Analysis

1. Business Overview Analysis

• business_model: Health Catalyst Inc operates in the healthcare data and analytics sector, providing solutions that support data-driven clinical and financial improvements within healthcare organizations.
• market_position: The company holds a competitive position with a focus on innovative healthcare analytics solutions, aimed at driving efficiency and value in the healthcare sector.
• recent_events_impact: The announcement of breakeven earnings per share and revenue growth indicates stable financial performance, though slightly reduced earnings expectations might reflect anticipated challenges or market conditions.

2. Financial Statement Analysis

• key_metrics:
• Profitability: Breakeven EPS indicates stable but not profit-generating performance for the quarter. EBITDA of $4 million suggests operational efficiency.
• Liquidity and Solvency: The analysis did not provide specifics on liquidity metrics or balance sheet details, thus requiring further data for comprehensive assessment.
• Efficiency: Revenue growth of 5.9% indicates moderate efficiency in operational performance.
• trends: The revenue growth, amidst a slight downturn in earnings expectations, suggests cautious market optimism and potential growth opportunities in the healthcare analytics market.
• strengths: Increase in revenue signifies a positive trend and a potentially favorable market environment.
• weaknesses: Earnings expectations declining slightly may indicate some operational or market challenges.

Valuation Assessment and Opportunity Analysis are less detailed due to limited data, but the high target price relative to the closing price suggests perceived undervaluation and potential investment opportunity. Reuters